Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 176 participants.
Also called NCT03262363
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 176 participants
- Sponsor
- Unidad de Investigacion Medica en Enfermedades Renales
- Registry
-
NCT03262363
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Mexico
- Registry status
- Unknown status
Technical summary
Registry record NCT03262363. Randomized; triple masking; primary purpose treatment. Start 2018-08-01 (anticipated); primary completion 2019-02-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy
- Acronym
- CURCUNRF2
- Condition
- Chronic Kidney Diseases
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Polymorphism
- Intervention (Combination product)
- Curcumin/NFE2L2 A>G
- Intervention (Combination product)
- Placebo/NFE2L2 A>G
- Lead sponsor
- Unidad de Investigacion Medica en Enfermedades Renales
Record details
- Record id
cardio:ct-nct03262363- Content hash
06972236deea088c84e9b8b4163312f49e3417946573440d9fb9650e76cef934